Protracted infusional 5-fluorouracil (5-FU) with bolus mitomycin in 5- FU-resistant colorectal cancer

Annals of Oncology

Volumn 11, Issue 2, 2000, Pages 235-237

  Chester, J D ^a   Dent, J T ^a   Wilson, G ^a   Ride, E ^a   Seymour, M T ^a  

^a Northern and Yorkshire Clinical Trials and Research Unit   (United Kingdom)

Author keywords

Colorectal; Fluorouracil; Infusion; Mitomycin

Indexed keywords

FLUOROURACIL; IRINOTECAN; MITOMYCIN C; OXALIPLATIN; PYRIDOXINE; WARFARIN;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BOLUS INJECTION; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; COLORECTAL CANCER; CONTINUOUS INFUSION; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; PRIORITY JOURNAL; SURVIVAL TIME; VOMITING;

EID: 0034058696     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008356017611     Document Type: Article

References (9)

1. de Gramont A, Bosset JF, Milan C et al. Randomised trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study. J Clin Oncol 1997; 15: 808-15.
2. Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16: 301-8.
3. Maughan TS, James RD, Kerr D et al. Preliminary results of a multicentre randomised trial comparing 3 chemotherapy regimens (de Gramont, Lokich, and Raltitrexed) in metastatic colorectal cancer. Proc Am Soc Clin Oncol 1999; 18: 262a (Abstr 1007).
4. Cunningham D. Setting a new standard - irinotecan (Campto) in the second-line therapy of colorectal cancer: Final results of two phase III studies and implications for clinical practice. Semin Oncol 1999; 26 (1, Suppl 5): 1-5.
5. Ross P, Norman A, Cunningham D et al. A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin-C in advanced colorectal cancer. Ann Oncol 1997; 8: 995-1001.
6. Cunningham D, Pyrhonen S, James RD et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413-8.
7. Rougier P, Van Cutsem E, Bajetta E et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352: 1407-12.
8. Price T, Cunningham D, Hickish T et al. Phase III study of chronomodulated vs. protracted venous infusional 5-fluorouracil both combined with mitomycin in first-line therapy for advanced colorectal carcinoma. Proc Am Soc Clin Oncol 1999; 17: 262a (Abstr 1008 and oral presentation).
9. Van Cutsem E, Rougier P, Droz JP et al. Clinical benefit of irinotecan (CPT-II) in metastatic colorectal cancer (CRC) resistant to 5-FU. Proc Am Soc Clin Oncol 1997; 16: 26Sa (Abstr 950).